NanoViricides Inc. Common Stock (NNVC)
Stock · AMEX · Health Care
$1.24as of 8/28/2026
Price chart
Open in TradingViewActive signals
200 SMA Touch90.3%
High Beta35.5%
Support level
$0.984125
Industry
Biotechnology: Pharmaceutical Preparations
About NNVC
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the tre…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 7
- Website
- www.nanoviricides.com/
Fundamentals
- 1-day range
- $1.34$1.39
- Market cap
- $35.56M
- P/E (trailing)
- —
- P/E (forward)
- -3.83
- EPS (trailing)
- $-0.44
- Dividend yield
- —
- Beta
- 1.87
- Avg. volume
- 898.8K
- Dividend pay date
- September 24, 2019
52-week range
$0.85$2.23
Forecasts
2 analyst ratings
Buy 88%
Hold 13%
Sell 0%
1-year price forecast
High
$6
+383.9%
Median
$6
+383.9%
Low
$6
+383.9%
NanoViricides Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- NNVCNanoViricides Inc. Common Stock$1.24▼ 3.12%Market cap $35.56MP/E —$0.85$2.23
- LTRNLantern Pharma Inc. Common Stock$2.08▼ 3.70%Market cap $35.47MP/E —$1.11$4.7
- IXHLIncannex Healthcare Inc. Common Stock$3.61▼ 2.17%Market cap $35.06MP/E —$2.49$20.64
- APLMApollomics Inc. Class A Ordinary Shares$26.6▲ 1.14%Market cap $37.33MP/E —$3.66$42.12
- ENLVEnlivex Ltd. Ordinary Shares$1.35▼ 8.47%Market cap $33.33MP/E 0.02$1.35$27.15
- HYPDHyperion DeFi Inc. Common Stock$3.25▼ 10.36%Market cap $40.47MP/E —$2.34$15
- BCTXBriaCell Therapeutics Corp. Common Shares$3.73▲ 0.54%Market cap $30.01MP/E —$3.68$20.4
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NNVC NanoViricides Inc. Common Stock | $35.56M | — | $1.24 | ▼ 3.12% | $0.85$2.23 |
| LTRN Lantern Pharma Inc. Common Stock | $35.47M | — | $2.08 | ▼ 3.70% | $1.11$4.7 |
| IXHL Incannex Healthcare Inc. Common Stock | $35.06M | — | $3.61 | ▼ 2.17% | $2.49$20.64 |
| APLM Apollomics Inc. Class A Ordinary Shares | $37.33M | — | $26.6 | ▲ 1.14% | $3.66$42.12 |
| ENLV Enlivex Ltd. Ordinary Shares | $33.33M | 0.02 | $1.35 | ▼ 8.47% | $1.35$27.15 |
| HYPD Hyperion DeFi Inc. Common Stock | $40.47M | — | $3.25 | ▼ 10.36% | $2.34$15 |
| BCTX BriaCell Therapeutics Corp. Common Shares | $30.01M | — | $3.73 | ▲ 0.54% | $3.68$20.4 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic EmergencyBenzinga · 8/28/2026
- NanoViricides Announces Expects Its Phase II Clinical Trial Of NV-387 Oral Gummies To Treat Bundibugyo Ebolavirus And Other Ebola Viruses To Begin Soon In The Democratic Republic Of Congobenzinga · 8/18/2026
- NanoViricides Announces Expects Its Phase II Clinical Trial Of NV-387 Oral Gummies To Treat Bundibugyo Ebolavirus And Other Ebola Viruses To Begin Soon In The Democratic Republic Of CongoBenzinga · 8/18/2026
- NanoViricides Wins DRC Approval To Begin Phase II Trial Of NV-387 Oral Gummies For EbolaBenzinga · 8/10/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 1.84M
- Total value held
- $1.67M
- Institutional holders
- 46
Top holders this quarter
- Unknown511.5K
- Unknown225.4K
- Unknown213.4K
- Unknown158.8K
- Unknown134.9K
- Unknown105.0K
- Unknown99.0K
- Unknown58.1K
- Unknown54.2K
- Unknown36.0K
See the full, filterable feed with live charts on the MarketWall dashboard.